<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315298</url>
  </required_header>
  <id_info>
    <org_study_id>6R88-COV-2040</org_study_id>
    <nct_id>NCT04315298</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</brief_title>
  <official_title>An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2:&#xD;
&#xD;
      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative&#xD;
      to the control arm in adult patients hospitalized with COVID-19 regardless of disease&#xD;
      severity strata.&#xD;
&#xD;
      Phase 3 Cohort 1:&#xD;
&#xD;
      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative&#xD;
      to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical&#xD;
      ventilation at baseline.&#xD;
&#xD;
      Phase 3 Cohort 2:&#xD;
&#xD;
      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative&#xD;
      to the control arm in adult patients hospitalized with COVID-19 receiving mechanical&#xD;
      ventilation at baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2 and Phase 3 Cohort 1 completed. Cohorts 2 and 3 terminated early based on Phase 3&#xD;
      Cohort 1 results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2020</start_date>
  <completion_date type="Actual">September 2, 2020</completion_date>
  <primary_completion_date type="Actual">July 24, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)</measure>
    <time_frame>Baseline and Day 4</time_frame>
    <description>Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp[ln(CRP at day 4/Baseline CRP)]-1. Negative numbers imply improvement in CRP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)</measure>
    <time_frame>Day 22</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)</measure>
    <time_frame>Day 22</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels.&#xD;
The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline.&#xD;
Resolution of fever is defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Resolution of fever is defined as body temperature &lt;=36.8 C (axilla or temporal) or&lt;= 37.2 C (oral) or &lt;37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge.&#xD;
Resolution of fever is defined only in participants with presence of fever at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Resolution of fever is defined as body temperature &lt;=36.8 C (axilla or temporal) or&lt;= 37.2 C (oral) or &lt;37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels.&#xD;
Resolution of fever is defined only in participants with presence of fever at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Resolution of fever defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)&#xD;
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NEWS2 Scoring System (Phase 2)</measure>
    <time_frame>Days 3, 5, 8, 11, 15 and 29</time_frame>
    <description>NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Fever (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive, Off Oxygen (Phase 2)</measure>
    <time_frame>At Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Resting Respiratory Rate &gt;24 Breaths/Min (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Hypoxemia (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Supplemental Oxygen Use (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Saturation ≥94% on Room Air (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator Free Days (Phase 2)</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization Among Survivors (Phase 2)</measure>
    <time_frame>Up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths Due to Any Cause</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Number of deaths due to any cause (All-Cause Mortality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Day 22</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Day 22</time_frame>
    <description>Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Day 22</time_frame>
    <description>Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Up to Day 29 and Day 60</time_frame>
    <description>Percentage of Participants who die through Day 29 and Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Up to Day 29 and Day 60</time_frame>
    <description>Percentage of Participants who die through Day 29 and Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>At Day 22</time_frame>
    <description>Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>At Day 22</time_frame>
    <description>Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>At Day 22</time_frame>
    <description>Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>At Day 22</time_frame>
    <description>Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)</measure>
    <time_frame>At Day 22</time_frame>
    <description>Percentage of Patients Discharged and Alive at Day 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>At Day 22</time_frame>
    <description>Percentage of Participants Discharged and Alive at Day 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery (Phase 3 Cohort 2)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Phase 3 Cohort 1 Time to Death (All-Cause Mortality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Time to Death (All-Cause Mortality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death (Phase 3 Cohort 2)</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Time to Death (All-Cause Mortality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</measure>
    <time_frame>Days 8, 15, 22 and 29</time_frame>
    <description>Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Days 8, 15, 22 and 29</time_frame>
    <description>Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)</measure>
    <time_frame>Days 8, 15, 22 and 29</time_frame>
    <description>Number of days of hospitalization among survivors (Phase 3 Cohort 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)</measure>
    <time_frame>Days 8, 15, 22 and 29</time_frame>
    <description>Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Serious Adverse Event</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 4 Neutropenia (ANC &lt;500/mm3)</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade &gt;=2 Infusion Related Reactions</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade &gt;=2 Hypersensitivity Reactions</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gastrointestinal Perforation</measure>
    <time_frame>Up to day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Leukocyte Values Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Leukocyte Values Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Hemoglobin Values Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Hemoglobin Values Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Platelet Count Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Platelet Count Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Total Bilirubin Values Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Total Bilirubin Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Creatinine Values Across Study Days (Phase 2)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Observed Creatinine Values Across Study Days (Phase 3)</measure>
    <time_frame>Days 1, 4, 15 and 29</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1912</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Sarilumab 200mg IV (P2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab 200mg IV (P3:C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab 400mg IV (P2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab 400mg IV (P3:C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab 800mg IV (P3:C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab 800mg IV (P3: C3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.</description>
    <arm_group_label>Sarilumab 200mg IV (P2)</arm_group_label>
    <arm_group_label>Sarilumab 200mg IV (P3:C1)</arm_group_label>
    <arm_group_label>Sarilumab 400mg IV (P2)</arm_group_label>
    <arm_group_label>Sarilumab 400mg IV (P3:C1)</arm_group_label>
    <arm_group_label>Sarilumab 800mg IV (P3: C3)</arm_group_label>
    <arm_group_label>Sarilumab 800mg IV (P3:C2)</arm_group_label>
    <other_name>Kevzara®</other_name>
    <other_name>REGN88</other_name>
    <other_name>SAR153191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple intravenous (IV) doses of placebo to match sarilumab administration</description>
    <arm_group_label>Sarilumab 200mg IV (P2)</arm_group_label>
    <arm_group_label>Sarilumab 200mg IV (P3:C1)</arm_group_label>
    <arm_group_label>Sarilumab 400mg IV (P2)</arm_group_label>
    <arm_group_label>Sarilumab 400mg IV (P3:C1)</arm_group_label>
    <arm_group_label>Sarilumab 800mg IV (P3: C3)</arm_group_label>
    <arm_group_label>Sarilumab 800mg IV (P3:C2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction&#xD;
             (PCR), result from any specimen (or other commercial or public health assay) within 2&#xD;
             weeks prior to randomization and no alternative explanation for current clinical&#xD;
             condition&#xD;
&#xD;
          -  Hospitalized with illness of any duration with evidence of pneumonia, requires&#xD;
             supplemental oxygen and/or assisted ventilation and meets one of the following:&#xD;
&#xD;
          -  Phase 2 and Phase 3 Cohort 1:&#xD;
&#xD;
        Meets 1 of the following criteria at baseline:&#xD;
&#xD;
          -  Severe disease OR&#xD;
&#xD;
          -  Critical disease OR&#xD;
&#xD;
          -  Multi-system organ dysfunction OR&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  Phase 3 Cohort 2:&#xD;
&#xD;
        Patients must be receiving mechanical ventilation to treat respiratory failure due to&#xD;
        COVID-19&#xD;
&#xD;
          -  Phase 3 Cohort 3:&#xD;
&#xD;
        Patients must be receiving supplemental oxygen to treat hypoxemia delivered by one of the&#xD;
        following devices:&#xD;
&#xD;
          -  Non-rebreather mask, OR&#xD;
&#xD;
          -  High-flow device with at least 50% FiO2, OR&#xD;
&#xD;
          -  Non-invasive positive pressure ventilator&#xD;
&#xD;
          -  Ability to provide informed consent signed by study patient or legally acceptable&#xD;
             representative&#xD;
&#xD;
          -  Willingness and ability to comply with study-related procedures/assessments&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the investigator, not expected to survive for more than 48 hours&#xD;
             from screening&#xD;
&#xD;
          -  Presence of any of the following abnormal laboratory values at screening: absolute&#xD;
             neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt; 5 x upper limit of normal (ULN), platelets &lt;50,000 per mm3&#xD;
&#xD;
          -  Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors&#xD;
             (JAKi) in the past 30 days or plans to receive during the study period&#xD;
&#xD;
          -  Current treatment with the simultaneous combination of leflunomide and methotrexate&#xD;
&#xD;
          -  Known active tuberculosis (TB), history of incompletely treated TB, suspected or known&#xD;
             extrapulmonary TB, suspected or known systemic bacterial or fungal infections&#xD;
&#xD;
          -  Participation in a double-blind clinical research study evaluating an investigational&#xD;
             product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the&#xD;
             screening visit (The use of remdesivir, hydroxychloroquine, or other treatments being&#xD;
             used for COVID-19 treatments in the context of an open-label study, Emergency Use&#xD;
             Authorization (EUA), compassionate use protocol or open-label use is permitted)&#xD;
&#xD;
          -  Any physical examination findings, and/or history of any illness, concomitant&#xD;
             medications or recent live vaccines that, in the opinion of the study investigator,&#xD;
             might confound the results of the study or pose an additional risk to the patient by&#xD;
             their participation in the study&#xD;
&#xD;
          -  Known systemic hypersensitivity to sarilumab or the excipients of the drug product&#xD;
&#xD;
          -  Phase 3 Cohort 2 and Cohort 3 only:&#xD;
&#xD;
          -  Known or suspected history of immunosuppression or immunodeficiency disorder&#xD;
&#xD;
          -  Patients who require renal replacement therapy for acute kidney injury at&#xD;
             randomization or who required renal replacement therapy within 72 hours prior to&#xD;
             randomization&#xD;
&#xD;
          -  Patients who have circulatory shock requiring vasopressors at randomization or within&#xD;
             24 hours prior to randomization&#xD;
&#xD;
          -  Use of extracorporeal life support (eg, ECMO) or, in the opinion of the investigator,&#xD;
             there is a high likelihood that extracorporeal life support will be initiated within&#xD;
             48 hours after randomization&#xD;
&#xD;
        NOTE: Other protocol defined inclusion / exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2021</results_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>coronavirus</keyword>
  <keyword>IL-6</keyword>
  <keyword>sarilumab</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 1946 participants screened, 1912 were randomized and 1861 were treated. 51 randomized participants were never treated: 26 withdrew consent, 14 investigator decision, 9 deaths, and 3 other.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 2: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="P2">
          <title>Phase 2: Sarilumab 200mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="P3">
          <title>Phase 2: Sarilumab 400mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="P4">
          <title>Phase 3 Cohort 1: Placebo - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="P5">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="P6">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="P7">
          <title>Phase 3 Cohort 1: Placebo - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="P8">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="P9">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="P10">
          <title>Phase 3 Cohort 1: Placebo - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="P11">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="P12">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="P13">
          <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="P14">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="P15">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="P16">
          <title>Phase 3 Cohort 2: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
        </group>
        <group group_id="P17">
          <title>Phase 3 Cohort 2: Sarilumab 800mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
        </group>
        <group group_id="P18">
          <title>Phase 3 Cohort 3: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
        </group>
        <group group_id="P19">
          <title>Phase 3 Cohort 3: Sarilumab 800mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="187"/>
                <participants group_id="P3" count="180"/>
                <participants group_id="P4" count="170"/>
                <participants group_id="P5" count="242"/>
                <participants group_id="P6" count="338"/>
                <participants group_id="P7" count="70"/>
                <participants group_id="P8" count="140"/>
                <participants group_id="P9" count="137"/>
                <participants group_id="P10" count="46"/>
                <participants group_id="P11" count="95"/>
                <participants group_id="P12" count="92"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="15"/>
                <participants group_id="P16" count="15"/>
                <participants group_id="P17" count="16"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="101"/>
                <participants group_id="P5" count="157"/>
                <participants group_id="P6" count="209"/>
                <participants group_id="P7" count="52"/>
                <participants group_id="P8" count="111"/>
                <participants group_id="P9" count="101"/>
                <participants group_id="P10" count="29"/>
                <participants group_id="P11" count="53"/>
                <participants group_id="P12" count="51"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="8"/>
                <participants group_id="P15" count="9"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="13"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="85"/>
                <participants group_id="P6" count="129"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="29"/>
                <participants group_id="P9" count="36"/>
                <participants group_id="P10" count="17"/>
                <participants group_id="P11" count="42"/>
                <participants group_id="P12" count="41"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="16"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="114"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="16"/>
                <participants group_id="P11" count="40"/>
                <participants group_id="P12" count="40"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 2: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="B2">
          <title>Phase 2: Sarilumab 200mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="B3">
          <title>Phase 2: Sarilumab 400mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="B4">
          <title>Phase 3 Cohort 1: Placebo - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="B5">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="B6">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="B7">
          <title>Phase 3 Cohort 1: Placebo - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="B8">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="B9">
          <title>Phase 3 Cohort 1 :Sarilumab 400mg IV - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="B10">
          <title>Phase 3 Cohort 1: Placebo - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="B11">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="B12">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="B13">
          <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="B14">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="B15">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="B16">
          <title>Phase 3 Cohort 2: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
        </group>
        <group group_id="B17">
          <title>Phase 3 Cohort 2: Sarilumab 800mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
        </group>
        <group group_id="B18">
          <title>Phase 3 Cohort 3: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
        </group>
        <group group_id="B19">
          <title>Phase 3 Cohort 3: Sarilumab 800mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
        </group>
        <group group_id="B20">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="187"/>
            <count group_id="B3" value="180"/>
            <count group_id="B4" value="170"/>
            <count group_id="B5" value="242"/>
            <count group_id="B6" value="338"/>
            <count group_id="B7" value="70"/>
            <count group_id="B8" value="140"/>
            <count group_id="B9" value="137"/>
            <count group_id="B10" value="46"/>
            <count group_id="B11" value="95"/>
            <count group_id="B12" value="92"/>
            <count group_id="B13" value="8"/>
            <count group_id="B14" value="12"/>
            <count group_id="B15" value="15"/>
            <count group_id="B16" value="15"/>
            <count group_id="B17" value="16"/>
            <count group_id="B18" value="6"/>
            <count group_id="B19" value="2"/>
            <count group_id="B20" value="1861"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="187"/>
                    <count group_id="B3" value="180"/>
                    <count group_id="B4" value="170"/>
                    <count group_id="B5" value="242"/>
                    <count group_id="B6" value="338"/>
                    <count group_id="B7" value="70"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="137"/>
                    <count group_id="B10" value="46"/>
                    <count group_id="B11" value="95"/>
                    <count group_id="B12" value="92"/>
                    <count group_id="B13" value="8"/>
                    <count group_id="B14" value="12"/>
                    <count group_id="B15" value="15"/>
                    <count group_id="B16" value="15"/>
                    <count group_id="B17" value="16"/>
                    <count group_id="B18" value="6"/>
                    <count group_id="B19" value="2"/>
                    <count group_id="B20" value="1861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="13.4"/>
                    <measurement group_id="B2" value="57.1" spread="14.6"/>
                    <measurement group_id="B3" value="56.3" spread="14.7"/>
                    <measurement group_id="B4" value="60.1" spread="15.0"/>
                    <measurement group_id="B5" value="58.5" spread="13.7"/>
                    <measurement group_id="B6" value="61.8" spread="14.2"/>
                    <measurement group_id="B7" value="61.2" spread="13.9"/>
                    <measurement group_id="B8" value="61.3" spread="15.1"/>
                    <measurement group_id="B9" value="62.2" spread="15.3"/>
                    <measurement group_id="B10" value="59.9" spread="13.7"/>
                    <measurement group_id="B11" value="59.1" spread="12.4"/>
                    <measurement group_id="B12" value="61.1" spread="15.1"/>
                    <measurement group_id="B13" value="58.3" spread="11.9"/>
                    <measurement group_id="B14" value="57.7" spread="7.0"/>
                    <measurement group_id="B15" value="65.2" spread="8.0"/>
                    <measurement group_id="B16" value="48.6" spread="15.3"/>
                    <measurement group_id="B17" value="52.9" spread="14.7"/>
                    <measurement group_id="B18" value="61.5" spread="9.1"/>
                    <measurement group_id="B19" value="66.0" spread="7.1"/>
                    <measurement group_id="B20" value="59.7" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="187"/>
                    <count group_id="B3" value="180"/>
                    <count group_id="B4" value="170"/>
                    <count group_id="B5" value="242"/>
                    <count group_id="B6" value="338"/>
                    <count group_id="B7" value="70"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="137"/>
                    <count group_id="B10" value="46"/>
                    <count group_id="B11" value="95"/>
                    <count group_id="B12" value="92"/>
                    <count group_id="B13" value="8"/>
                    <count group_id="B14" value="12"/>
                    <count group_id="B15" value="15"/>
                    <count group_id="B16" value="15"/>
                    <count group_id="B17" value="16"/>
                    <count group_id="B18" value="6"/>
                    <count group_id="B19" value="2"/>
                    <count group_id="B20" value="1861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="111"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="59"/>
                    <measurement group_id="B9" value="51"/>
                    <measurement group_id="B10" value="21"/>
                    <measurement group_id="B11" value="41"/>
                    <measurement group_id="B12" value="34"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="617"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="175"/>
                    <measurement group_id="B6" value="227"/>
                    <measurement group_id="B7" value="45"/>
                    <measurement group_id="B8" value="81"/>
                    <measurement group_id="B9" value="86"/>
                    <measurement group_id="B10" value="25"/>
                    <measurement group_id="B11" value="54"/>
                    <measurement group_id="B12" value="58"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="11"/>
                    <measurement group_id="B16" value="11"/>
                    <measurement group_id="B17" value="11"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="1244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="187"/>
                    <count group_id="B3" value="180"/>
                    <count group_id="B4" value="170"/>
                    <count group_id="B5" value="242"/>
                    <count group_id="B6" value="338"/>
                    <count group_id="B7" value="70"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="137"/>
                    <count group_id="B10" value="46"/>
                    <count group_id="B11" value="95"/>
                    <count group_id="B12" value="92"/>
                    <count group_id="B13" value="8"/>
                    <count group_id="B14" value="12"/>
                    <count group_id="B15" value="15"/>
                    <count group_id="B16" value="15"/>
                    <count group_id="B17" value="16"/>
                    <count group_id="B18" value="6"/>
                    <count group_id="B19" value="2"/>
                    <count group_id="B20" value="1861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="115"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="30"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="27"/>
                    <measurement group_id="B12" value="21"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="10"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="526"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="119"/>
                    <measurement group_id="B6" value="163"/>
                    <measurement group_id="B7" value="40"/>
                    <measurement group_id="B8" value="80"/>
                    <measurement group_id="B9" value="88"/>
                    <measurement group_id="B10" value="26"/>
                    <measurement group_id="B11" value="46"/>
                    <measurement group_id="B12" value="47"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="10"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="994"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="22"/>
                    <measurement group_id="B12" value="24"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="187"/>
                    <count group_id="B3" value="180"/>
                    <count group_id="B4" value="170"/>
                    <count group_id="B5" value="242"/>
                    <count group_id="B6" value="338"/>
                    <count group_id="B7" value="70"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="137"/>
                    <count group_id="B10" value="46"/>
                    <count group_id="B11" value="95"/>
                    <count group_id="B12" value="92"/>
                    <count group_id="B13" value="8"/>
                    <count group_id="B14" value="12"/>
                    <count group_id="B15" value="15"/>
                    <count group_id="B16" value="15"/>
                    <count group_id="B17" value="16"/>
                    <count group_id="B18" value="6"/>
                    <count group_id="B19" value="2"/>
                    <count group_id="B20" value="1861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="65"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="35"/>
                    <measurement group_id="B9" value="25"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="23"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="9"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="127"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="45"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="29"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="7"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="677"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="102"/>
                    <measurement group_id="B6" value="137"/>
                    <measurement group_id="B7" value="29"/>
                    <measurement group_id="B8" value="51"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="21"/>
                    <measurement group_id="B11" value="40"/>
                    <measurement group_id="B12" value="41"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP levels</title>
          <description>Baseline C-Reactive Protein (CRP)</description>
          <population>ITT population</population>
          <units>milligrams per Liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="180"/>
                    <count group_id="B3" value="171"/>
                    <count group_id="B4" value="162"/>
                    <count group_id="B5" value="223"/>
                    <count group_id="B6" value="314"/>
                    <count group_id="B7" value="64"/>
                    <count group_id="B8" value="133"/>
                    <count group_id="B9" value="114"/>
                    <count group_id="B10" value="44"/>
                    <count group_id="B11" value="89"/>
                    <count group_id="B12" value="86"/>
                    <count group_id="B13" value="8"/>
                    <count group_id="B14" value="11"/>
                    <count group_id="B15" value="14"/>
                    <count group_id="B16" value="13"/>
                    <count group_id="B17" value="15"/>
                    <count group_id="B18" value="6"/>
                    <count group_id="B19" value="2"/>
                    <count group_id="B20" value="1736"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192.537" spread="122.295"/>
                    <measurement group_id="B2" value="191.997" spread="124.583"/>
                    <measurement group_id="B3" value="195.037" spread="119.274"/>
                    <measurement group_id="B4" value="167.476" spread="115.020"/>
                    <measurement group_id="B5" value="187.573" spread="108.085"/>
                    <measurement group_id="B6" value="179.085" spread="103.837"/>
                    <measurement group_id="B7" value="111.933" spread="81.789"/>
                    <measurement group_id="B8" value="127.811" spread="116.058"/>
                    <measurement group_id="B9" value="129.355" spread="136.734"/>
                    <measurement group_id="B10" value="205.978" spread="118.459"/>
                    <measurement group_id="B11" value="235.395" spread="280.665"/>
                    <measurement group_id="B12" value="232.924" spread="128.435"/>
                    <measurement group_id="B13" value="141.207" spread="71.915"/>
                    <measurement group_id="B14" value="203.356" spread="118.998"/>
                    <measurement group_id="B15" value="185.740" spread="91.237"/>
                    <measurement group_id="B16" value="226.846" spread="112.047"/>
                    <measurement group_id="B17" value="212.920" spread="107.702"/>
                    <measurement group_id="B18" value="177.334" spread="79.490"/>
                    <measurement group_id="B19" value="258.081" spread="200.704"/>
                    <measurement group_id="B20" value="180.010" spread="131.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)</title>
        <description>Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp[ln(CRP at day 4/Baseline CRP)]-1. Negative numbers imply improvement in CRP.</description>
        <time_frame>Baseline and Day 4</time_frame>
        <population>Phase 2 mITT population: The modified intention-to-treat (mITT) population includes all randomized participants who received at least one dose of the study drug and have high baseline IL-6 levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)</title>
          <description>Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp[ln(CRP at day 4/Baseline CRP)]-1. Negative numbers imply improvement in CRP.</description>
          <population>Phase 2 mITT population: The modified intention-to-treat (mITT) population includes all randomized participants who received at least one dose of the study drug and have high baseline IL-6 levels.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.077"/>
                    <measurement group_id="O2" value="-0.77" spread="0.018"/>
                    <measurement group_id="O3" value="-0.78" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on the ANCOVA model for differences between treatment groups in terms of [ln(CRP at day 4 ) - ln(baseline CRP)].</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean (log scale)</param_type>
            <param_value>-1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.456</ci_lower_limit>
            <ci_upper_limit>-1.035</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is based on the ANCOVA model for differences between treatment groups in terms of [ln(CRP at day 4 ) - ln(baseline CRP)].</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean (log scale)</param_type>
            <param_value>-1.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.511</ci_lower_limit>
            <ci_upper_limit>-1.090</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 1 Intention-to-treat (ITT) participants with a disease severity of critical and mechanical ventilation at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1 Intention-to-treat (ITT) participants with a disease severity of critical and mechanical ventilation at baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="23.6" upper_limit="47.4"/>
                    <measurement group_id="O2" value="43.3" lower_limit="33.7" upper_limit="52.8"/>
                    <measurement group_id="O3" value="43.2" lower_limit="34.7" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3707</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>21.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3261</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 2 ITT participants receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 2: Sarilumab 800mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 2 ITT participants receiving mechanical ventilation at baseline</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="35.2" upper_limit="84.8"/>
                    <measurement group_id="O2" value="68.8" lower_limit="46.0" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7328</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.2</ci_lower_limit>
            <ci_upper_limit>36.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)</title>
        <description>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 mITT population: The modified intention-to-treat (mITT) population includes all randomized participants who received at least one dose of the study drug and have high baseline IL-6 levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)</title>
          <description>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 2 mITT population: The modified intention-to-treat (mITT) population includes all randomized participants who received at least one dose of the study drug and have high baseline IL-6 levels.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="15.0" lower_limit="12.0" upper_limit="21.0"/>
                    <measurement group_id="O3" value="14.0" lower_limit="10.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5687</p_value>
            <p_value_desc>P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7014</p_value>
            <p_value_desc>P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)</title>
        <description>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels.&#xD;
The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 Severe and Critical ITT population. The intention-to-treat (ITT) population includes all randomized patients who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)</title>
          <description>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels.&#xD;
The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 2 Severe and Critical ITT population. The intention-to-treat (ITT) population includes all randomized patients who received at least one dose of the study drug.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="10.0" upper_limit="28.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="11.0" upper_limit="19.0"/>
                    <measurement group_id="O3" value="13.0" lower_limit="10.0" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3622</p_value>
            <p_value_desc>P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5802</p_value>
            <p_value_desc>P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)</title>
        <description>Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline.&#xD;
Resolution of fever is defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary).</description>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 ITT population with presence of fever at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)</title>
          <description>Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline.&#xD;
Resolution of fever is defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary).</description>
          <population>Phase 2 ITT population with presence of fever at baseline</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="18.0" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="18.0" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2340</p_value>
            <p_value_desc>P-value based on log-rank test stratified by disease severity (severe, critical and MSOD) and use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6949</p_value>
            <p_value_desc>P-value based on log-rank test stratified by disease severity (severe, critical and MSOD) and use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)</title>
        <description>Resolution of fever is defined as body temperature &lt;=36.8 C (axilla or temporal) or&lt;= 37.2 C (oral) or &lt;37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge.&#xD;
Resolution of fever is defined only in participants with presence of fever at baseline.</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population with presence of fever at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)</title>
          <description>Resolution of fever is defined as body temperature &lt;=36.8 C (axilla or temporal) or&lt;= 37.2 C (oral) or &lt;37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge.&#xD;
Resolution of fever is defined only in participants with presence of fever at baseline.</description>
          <population>Phase 2 ITT population with presence of fever at baseline</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="5.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="15.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="29.0" lower_limit="16.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="20.5" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Multisystem Organ Dysfunction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="17.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="18.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3151</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1884</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4356</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0371</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8923</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6940</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)</title>
        <description>Resolution of fever is defined as body temperature &lt;=36.8 C (axilla or temporal) or&lt;= 37.2 C (oral) or &lt;37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels.&#xD;
Resolution of fever is defined only in participants with presence of fever at baseline.</description>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 ITT population with presence of fever and IL-6 measurement reported at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)</title>
          <description>Resolution of fever is defined as body temperature &lt;=36.8 C (axilla or temporal) or&lt;= 37.2 C (oral) or &lt;37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels.&#xD;
Resolution of fever is defined only in participants with presence of fever at baseline.</description>
          <population>Phase 2 ITT population with presence of fever and IL-6 measurement reported at baseline</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe Baseline IL-6 &lt; 87.04 picograms per milliliter (pg/mL) Median</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="4.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="3.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Baseline IL-6 &gt;= 87.04pg/mL (Median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="3.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="4.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Baseline IL-6 &lt; 166.68pg/mL (Median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="2.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="16.5" lower_limit="5.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="17.0" lower_limit="5.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Baseline IL-6 &gt;= 166.68pg/mL (Median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="16.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="25.0" lower_limit="12.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Baseline IL-6 &lt;254.95 pg/mL (Median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="14.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="9.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="15.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Baseline IL-6 &gt;= 254.95 pg/mL (Median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="2.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="5.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &lt; 87.04 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0832</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &lt; 87.04 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1369</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>4.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &gt;= 87.04 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9636</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &gt;= 87.04 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &lt; 166.68pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7380</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &lt;166.68pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7342</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &gt;= 166.68pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1934</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>16.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &gt;= 166.68pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0159</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>5.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>23.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &lt;254.95 pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6281</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>8.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &lt;254.95 pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4971</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>6.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &gt;= 254.95 pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2990</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &gt;= 254.95 pg/mL (Median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9360</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>4.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)</title>
        <description>Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)</title>
          <description>Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="5.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="11.0" lower_limit="6.0" upper_limit="NA">Less than 50% of participants experience the event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.0" upper_limit="NA">Less than 50% of participants experience the event</measurement>
                    <measurement group_id="O2" value="20.0" lower_limit="12.0" upper_limit="NA">Less than 50% of participants experience the event</measurement>
                    <measurement group_id="O3" value="11.0" lower_limit="8.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="9.0" upper_limit="NA">Less than 50% of participants experience the event</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="12.0" upper_limit="NA">Less than 50% of participants experience the event</measurement>
                    <measurement group_id="O3" value="19.0" lower_limit="10.0" upper_limit="NA">Less than 50% of participants experience the event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9032</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0052</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1168</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3753</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4956</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8439</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)</title>
        <description>Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population with IL-6 measurement reported at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)</title>
          <description>Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
          <population>Phase 2 ITT population with IL-6 measurement reported at baseline</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe Participants Baseline IL-6 &lt; 67.11pg/mL (median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.5" lower_limit="4.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Participants Baseline IL-6 &gt;= 67.11pg/mL (median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="8.5" lower_limit="5.0" upper_limit="11.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="11.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Critical Participants Baseline IL-6 &lt; 131.90pg/mL (median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="6.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O2" value="17.0" lower_limit="8.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O3" value="8.5" lower_limit="7.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Critical Participants Baseline IL-6 &gt;= 131.90pg/mL (median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="6.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="12.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O3" value="14.0" lower_limit="8.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSOD / Immunocompromised Participants Baseline IL-6 &lt; 254.95pg/mL (median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="3.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="7.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O3" value="24.0" lower_limit="7.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSOD / Immunocompromised Participants Baseline IL-6 &gt;= 254.95pg/mL (median)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="9.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="8.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                    <measurement group_id="O3" value="19.0" lower_limit="13.0" upper_limit="NA">Less than 50% of participants experienced an event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &lt; 67.11 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3890</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &gt;= 67.11pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7838</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &lt; 67.11 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2370</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe Baseline IL-6 &gt;= 67.11pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &lt; 131.90 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1740</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &gt;= 131.90 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3664</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &lt; 131.90 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7318</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical Baseline IL-6 &gt;= 131.90 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4155</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &lt; 254.95 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6262</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &gt;= 254.95 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5530</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &lt; 254.95 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8775</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD Baseline IL-6 &gt;= 254.95 pg/mL (median)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7485</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)</title>
        <description>Resolution of fever defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)&#xD;
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)</title>
          <description>Resolution of fever defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)&#xD;
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="4.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="7.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="22.0" lower_limit="8.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="8.5" lower_limit="7.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="8.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="9.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="24.0" lower_limit="9.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4556</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0248</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6842</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0671</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6146</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9730</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)</title>
        <description>Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)</title>
          <description>Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 2 ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94.0"/>
                    <measurement group_id="O3" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 1 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="88.0"/>
                    <measurement group_id="O3" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 3 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="66.0"/>
                    <measurement group_id="O3" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 5 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 8 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="46.0"/>
                    <measurement group_id="O3" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 11 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="74.0"/>
                    <measurement group_id="O3" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 15 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="86.0"/>
                    <measurement group_id="O3" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Severe Day 29 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                    <measurement group_id="O2" value="92.0"/>
                    <measurement group_id="O3" value="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="28.7"/>
                    <measurement group_id="O3" value="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 1 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1"/>
                    <measurement group_id="O2" value="71.3"/>
                    <measurement group_id="O3" value="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="19.1"/>
                    <measurement group_id="O3" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 3 Ordinal Scale = Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 5 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 8 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="41.5"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="11.7"/>
                    <measurement group_id="O3" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 11 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="19.1"/>
                    <measurement group_id="O3" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 15 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="37.2"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical Day 29 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="46.8"/>
                    <measurement group_id="O3" value="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 1 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="95.3"/>
                    <measurement group_id="O3" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 3 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5"/>
                    <measurement group_id="O2" value="88.4"/>
                    <measurement group_id="O3" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 5 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="69.8"/>
                    <measurement group_id="O3" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 8 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="11.6"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 11 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="34.9"/>
                    <measurement group_id="O3" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="34.9"/>
                    <measurement group_id="O3" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 15 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="41.9"/>
                    <measurement group_id="O3" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD Day 29 Ordinal Scale = Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)</title>
        <description>NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)</title>
          <description>NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).</description>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="4.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="9.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="25.0" lower_limit="19.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="15.0" lower_limit="10.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="18.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="24.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="23.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6987</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0453</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9734</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0040</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No)</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9551</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8722</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NEWS2 Scoring System (Phase 2)</title>
        <description>NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).</description>
        <time_frame>Days 3, 5, 8, 11, 15 and 29</time_frame>
        <population>Phase 2 ITT population with NEWS2 score reported at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NEWS2 Scoring System (Phase 2)</title>
          <description>NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).</description>
          <population>Phase 2 ITT population with NEWS2 score reported at baseline</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="2.29"/>
                    <measurement group_id="O2" value="0.14" spread="2.69"/>
                    <measurement group_id="O3" value="0.03" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="3.18"/>
                    <measurement group_id="O2" value="0.00" spread="2.98"/>
                    <measurement group_id="O3" value="0.03" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="3.05"/>
                    <measurement group_id="O2" value="-0.22" spread="3.33"/>
                    <measurement group_id="O3" value="-0.31" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="3.53"/>
                    <measurement group_id="O2" value="-0.27" spread="3.65"/>
                    <measurement group_id="O3" value="-0.29" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="3.55"/>
                    <measurement group_id="O2" value="-0.45" spread="3.91"/>
                    <measurement group_id="O3" value="-0.48" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="4.12"/>
                    <measurement group_id="O2" value="-1.12" spread="4.23"/>
                    <measurement group_id="O3" value="-1.34" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Fever (Phase 2)</title>
        <description>Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)</description>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Fever (Phase 2)</title>
          <description>Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)</description>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.92"/>
                    <measurement group_id="O2" value="4.2" spread="4.37"/>
                    <measurement group_id="O3" value="5.8" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive, Off Oxygen (Phase 2)</title>
        <time_frame>At Day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive, Off Oxygen (Phase 2)</title>
          <population>Phase 2 ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="81.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="92.0" lower_limit="84.5" upper_limit="99.5"/>
                    <measurement group_id="O3" value="70.6" lower_limit="58.1" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="26.4" upper_limit="55.4"/>
                    <measurement group_id="O2" value="50.0" lower_limit="39.9" upper_limit="60.1"/>
                    <measurement group_id="O3" value="61.4" lower_limit="51.2" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="17.3" upper_limit="58.9"/>
                    <measurement group_id="O2" value="39.5" lower_limit="24.9" upper_limit="54.1"/>
                    <measurement group_id="O3" value="34.1" lower_limit="19.6" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0353</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3187</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0261</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9117</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7584</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Resting Respiratory Rate &gt;24 Breaths/Min (Phase 2)</title>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Resting Respiratory Rate &gt;24 Breaths/Min (Phase 2)</title>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="10.29"/>
                    <measurement group_id="O2" value="7.3" spread="8.21"/>
                    <measurement group_id="O3" value="8.2" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Hypoxemia (Phase 2)</title>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Hypoxemia (Phase 2)</title>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="14.16"/>
                    <measurement group_id="O2" value="14.5" spread="11.96"/>
                    <measurement group_id="O3" value="16.4" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Supplemental Oxygen Use (Phase 2)</title>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Supplemental Oxygen Use (Phase 2)</title>
          <population>Phase 2 ITT population</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="14.15"/>
                    <measurement group_id="O2" value="14.1" spread="11.92"/>
                    <measurement group_id="O3" value="16.2" spread="14.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Saturation ≥94% on Room Air (Phase 2)</title>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Saturation ≥94% on Room Air (Phase 2)</title>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="6.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="3.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="5.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="4.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="4.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0385</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Severe</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0782</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2436</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: Critical</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3223</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4670</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Disease Severity: MSOD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3728</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ventilator Free Days (Phase 2)</title>
        <description>Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Phase 2 ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ventilator Free Days (Phase 2)</title>
          <description>Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline</description>
          <population>Phase 2 ITT population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="4.2"/>
                    <measurement group_id="O2" value="19.7" spread="4.7"/>
                    <measurement group_id="O3" value="15.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="9.6"/>
                    <measurement group_id="O2" value="7.6" spread="8.5"/>
                    <measurement group_id="O3" value="10.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="5.5"/>
                    <measurement group_id="O2" value="4.6" spread="6.5"/>
                    <measurement group_id="O3" value="3.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)</title>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 ITT population not on Invasive mechanical ventilation or ECMO at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)</title>
          <population>Phase 2 ITT population not on Invasive mechanical ventilation or ECMO at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease Severity: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: Critical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Severity: MSOD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)</title>
        <time_frame>Up to Day 29</time_frame>
        <population>Phase 2 ITT population participants who were not in ICU at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)</title>
          <population>Phase 2 ITT population participants who were not in ICU at baseline</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="11.0"/>
                    <measurement group_id="O2" value="11.4" spread="10.5"/>
                    <measurement group_id="O3" value="13.8" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization Among Survivors (Phase 2)</title>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 2 ITT population participants with a hospital discharge date on or before Day 29</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization Among Survivors (Phase 2)</title>
          <population>Phase 2 ITT population participants with a hospital discharge date on or before Day 29</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.3"/>
                    <measurement group_id="O2" value="7.3" spread="1.3"/>
                    <measurement group_id="O3" value="7.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="2.0"/>
                    <measurement group_id="O2" value="13.5" spread="2.2"/>
                    <measurement group_id="O3" value="13.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="1.8"/>
                    <measurement group_id="O2" value="21.2" spread="1.7"/>
                    <measurement group_id="O3" value="21.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="2.5"/>
                    <measurement group_id="O2" value="27.5" spread="2.2"/>
                    <measurement group_id="O3" value="28.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths Due to Any Cause</title>
        <description>Number of deaths due to any cause (All-Cause Mortality)</description>
        <time_frame>Up to day 60</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1:Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths Due to Any Cause</title>
          <description>Number of deaths due to any cause (All-Cause Mortality)</description>
          <population>ITT population</population>
          <units>deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="114"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="40"/>
                    <measurement group_id="O12" value="40"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="6"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 1 Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1 Critical ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="46.6" upper_limit="61.6"/>
                    <measurement group_id="O2" value="56.6" lower_limit="50.4" upper_limit="62.9"/>
                    <measurement group_id="O3" value="51.5" lower_limit="46.2" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5851</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>12.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5767</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22</description>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22</description>
          <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="14.9" upper_limit="36.7"/>
                    <measurement group_id="O2" value="30.8" lower_limit="21.9" upper_limit="39.6"/>
                    <measurement group_id="O3" value="31.8" lower_limit="23.9" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4777</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4202</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22</description>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 1 Critical ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22</description>
          <population>Phase 3 Cohort 1 Critical ITT</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="42.5" upper_limit="57.5"/>
                    <measurement group_id="O2" value="49.6" lower_limit="43.3" upper_limit="55.9"/>
                    <measurement group_id="O3" value="45.3" lower_limit="40.0" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9696</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3152</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Percentage of Participants who die through Day 29 and Day 60</description>
        <time_frame>Up to Day 29 and Day 60</time_frame>
        <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Percentage of Participants who die through Day 29 and Day 60</description>
          <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Through Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" lower_limit="29.7" upper_limit="54.2"/>
                    <measurement group_id="O2" value="33.7" lower_limit="24.6" upper_limit="42.7"/>
                    <measurement group_id="O3" value="36.4" lower_limit="28.2" upper_limit="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Through Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" lower_limit="39.2" upper_limit="64.1"/>
                    <measurement group_id="O2" value="37.5" lower_limit="28.2" upper_limit="46.8"/>
                    <measurement group_id="O3" value="39.4" lower_limit="31.1" upper_limit="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Through Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3217</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.8</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Through Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4630</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.2</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Through Day 60</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0971</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-13.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Through Day 60</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1193</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.4</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Percentage of Participants who die through Day 29 and Day 60</description>
        <time_frame>Up to Day 29 and Day 60</time_frame>
        <population>Phase 3 Cohort 1 Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Percentage of Participants who die through Day 29 and Day 60</description>
          <population>Phase 3 Cohort 1 Critical ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Through Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="18.8" upper_limit="31.8"/>
                    <measurement group_id="O2" value="24.8" lower_limit="19.4" upper_limit="30.2"/>
                    <measurement group_id="O3" value="30.5" lower_limit="25.6" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Through Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="27.6" upper_limit="41.9"/>
                    <measurement group_id="O2" value="28.9" lower_limit="23.2" upper_limit="34.6"/>
                    <measurement group_id="O3" value="33.7" lower_limit="28.7" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Through Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8844</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Through Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2247</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Through Day 60</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2102</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-13.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Through Day 60</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8292</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.4</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)</description>
        <time_frame>At Day 22</time_frame>
        <population>Phase 3 Cohort 1 - Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)</description>
          <population>Phase 3 Cohort 1 - Critical population receiving mechanical ventilation at baseline</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="23.6" upper_limit="47.4"/>
                    <measurement group_id="O2" value="46.2" lower_limit="36.6" upper_limit="55.7"/>
                    <measurement group_id="O3" value="44.7" lower_limit="36.2" upper_limit="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2203</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2483</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>At Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" lower_limit="22.1" upper_limit="45.7"/>
                    <measurement group_id="O2" value="38.5" lower_limit="29.1" upper_limit="47.8"/>
                    <measurement group_id="O3" value="40.2" lower_limit="31.8" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6020</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4342</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)</description>
        <time_frame>At Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="51.4" upper_limit="66.2"/>
                    <measurement group_id="O2" value="63.6" lower_limit="57.6" upper_limit="69.7"/>
                    <measurement group_id="O3" value="55.9" lower_limit="50.6" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2896</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5355</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>At Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="44.8" upper_limit="59.9"/>
                    <measurement group_id="O2" value="52.5" lower_limit="46.2" upper_limit="58.8"/>
                    <measurement group_id="O3" value="47.6" lower_limit="42.3" upper_limit="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9210</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3174</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 1 Critical populations receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1 Critical populations receiving mechanical ventilation at baseline</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="27.0" lower_limit="18.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="18.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0705</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1800</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 1 Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1 Critical ITT population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="13.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="16.0" lower_limit="12.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="18.0" lower_limit="14.0" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1831</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8770</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 2 Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 2: Sarilumab 800mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
        </group_list>
        <measure>
          <title>Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 2 Critical population receiving mechanical ventilation at baseline</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="6.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="9.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7103</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="21.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="21.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1512</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2952</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</title>
        <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)</title>
          <description>The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows:&#xD;
1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="16.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="19.0" lower_limit="16.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="23.0" lower_limit="18.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2297</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8651</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="14.9" upper_limit="36.7"/>
                    <measurement group_id="O2" value="24.0" lower_limit="15.8" upper_limit="32.3"/>
                    <measurement group_id="O3" value="23.5" lower_limit="16.3" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8864</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7500</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)</title>
        <time_frame>Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)</title>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="11.4" upper_limit="22.7"/>
                    <measurement group_id="O2" value="15.7" lower_limit="11.1" upper_limit="20.3"/>
                    <measurement group_id="O3" value="17.5" lower_limit="13.4" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6858</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9173</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)</title>
        <description>Percentage of Patients Discharged and Alive at Day 22</description>
        <time_frame>At Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)</title>
          <description>Percentage of Patients Discharged and Alive at Day 22</description>
          <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="12.2" upper_limit="33.0"/>
                    <measurement group_id="O2" value="26.9" lower_limit="18.4" upper_limit="35.4"/>
                    <measurement group_id="O3" value="26.5" lower_limit="19.0" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5239</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>17.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5809</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>15.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Percentage of Participants Discharged and Alive at Day 22</description>
        <time_frame>At Day 22</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Percentage of Participants Discharged and Alive at Day 22</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="40.1" upper_limit="55.2"/>
                    <measurement group_id="O2" value="47.5" lower_limit="41.2" upper_limit="53.8"/>
                    <measurement group_id="O3" value="42.6" lower_limit="37.3" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9343</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2822</p_value>
            <p_value_desc>P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
          <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="29.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="28.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4519</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2818</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="18.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="23.0" lower_limit="17.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="27.0" lower_limit="22.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4674</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8503</p_value>
            <p_value_desc>P-value from stratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery (Phase 3 Cohort 2)</title>
        <description>Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
        <time_frame>Up to day 29</time_frame>
        <population>Phase 3 Cohort 2 population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 2: Sarilumab 800mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery (Phase 3 Cohort 2)</title>
          <description>Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)</description>
          <population>Phase 3 Cohort 2 population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="12.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="22.0" lower_limit="13.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6156</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Phase 3 Cohort 1 Time to Death (All-Cause Mortality)</description>
        <time_frame>Up to day 60</time_frame>
        <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Phase 3 Cohort 1 Time to Death (All-Cause Mortality)</description>
          <population>Phase 3 Cohort 1 Critical population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" lower_limit="17.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0843</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1576</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Time to Death (All-Cause Mortality)</description>
        <time_frame>Up to day 60</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Time to Death (All-Cause Mortality)</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1980</p_value>
            <p_value_desc>P-value from stratified log-rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7973</p_value>
            <p_value_desc>P-value from stratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death (Phase 3 Cohort 2)</title>
        <description>Time to Death (All-Cause Mortality)</description>
        <time_frame>Up to day 60</time_frame>
        <population>Phase 3 Cohort 2 population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 2: Sarilumab 800mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death (Phase 3 Cohort 2)</title>
          <description>Time to Death (All-Cause Mortality)</description>
          <population>Phase 3 Cohort 2 population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="17.0" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of participants experienced an event response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5023</p_value>
            <p_value_desc>P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
        <description>Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)</description>
        <time_frame>Days 8, 15, 22 and 29</time_frame>
        <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)</title>
          <description>Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)</description>
          <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ventilator-free days up to Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.4"/>
                    <measurement group_id="O2" value="0.8" spread="1.7"/>
                    <measurement group_id="O3" value="0.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-free days up to Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="4.0"/>
                    <measurement group_id="O2" value="2.8" spread="4.4"/>
                    <measurement group_id="O3" value="2.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-free days up to Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="6.8"/>
                    <measurement group_id="O2" value="5.5" spread="7.3"/>
                    <measurement group_id="O3" value="4.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-free days up to Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="9.9"/>
                    <measurement group_id="O2" value="8.7" spread="10.4"/>
                    <measurement group_id="O3" value="8.0" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2804</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5023</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3821</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9737</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3179</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6302</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2862</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4509</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)</description>
        <time_frame>Days 8, 15, 22 and 29</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)</description>
          <population>Phase 3 Cohort 1: Critical ITT population</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ventilator-free days up to Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.3"/>
                    <measurement group_id="O2" value="3.5" spread="3.3"/>
                    <measurement group_id="O3" value="3.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-free days up to Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="6.5"/>
                    <measurement group_id="O2" value="7.2" spread="6.4"/>
                    <measurement group_id="O3" value="6.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-free days up to Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="9.7"/>
                    <measurement group_id="O2" value="11.3" spread="9.4"/>
                    <measurement group_id="O3" value="9.9" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventilator-free days up to Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="12.8"/>
                    <measurement group_id="O2" value="15.5" spread="12.4"/>
                    <measurement group_id="O3" value="13.9" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5640</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1602</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9144</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1450</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8378</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1988</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8556</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ventilator-free days up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2630</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)</title>
        <description>Number of days of hospitalization among survivors (Phase 3 Cohort 1)</description>
        <time_frame>Days 8, 15, 22 and 29</time_frame>
        <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)</title>
          <description>Number of days of hospitalization among survivors (Phase 3 Cohort 1)</description>
          <population>Phase 3 Cohort 1: Critical population receiving mechanical ventilation at baseline</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalized up to Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="0.9"/>
                    <measurement group_id="O2" value="7.8" spread="0.6"/>
                    <measurement group_id="O3" value="8.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized up to Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="1.5"/>
                    <measurement group_id="O2" value="14.4" spread="1.5"/>
                    <measurement group_id="O3" value="14.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized up to Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="2.3"/>
                    <measurement group_id="O2" value="21.6" spread="1.3"/>
                    <measurement group_id="O3" value="21.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized up to Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="1.8"/>
                    <measurement group_id="O2" value="28.5" spread="1.4"/>
                    <measurement group_id="O3" value="28.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3662</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0820</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6984</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9833</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1436</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4190</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6520</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8010</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)</title>
        <description>Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)</description>
        <time_frame>Days 8, 15, 22 and 29</time_frame>
        <population>Phase 3 Cohort 1: Critical ITT population participants with a hospital discharge date on or before Day 29</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)</title>
          <description>Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)</description>
          <population>Phase 3 Cohort 1: Critical ITT population participants with a hospital discharge date on or before Day 29</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalized up to Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="1.2"/>
                    <measurement group_id="O2" value="7.4" spread="1.3"/>
                    <measurement group_id="O3" value="7.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized up to Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="2.0"/>
                    <measurement group_id="O2" value="13.8" spread="1.9"/>
                    <measurement group_id="O3" value="13.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized up to Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="2.0"/>
                    <measurement group_id="O2" value="21.1" spread="1.8"/>
                    <measurement group_id="O3" value="21.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized up to Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="1.4"/>
                    <measurement group_id="O2" value="28.2" spread="1.8"/>
                    <measurement group_id="O3" value="28.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3724</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7034</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5841</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6648</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4624</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 22</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2546</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5312</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hospitalized up to Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3039</p_value>
            <p_value_desc>p-value using two-sample t-test</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Serious Adverse Event</title>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Serious Adverse Event</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="119"/>
                    <measurement group_id="O6" value="183"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="30"/>
                    <measurement group_id="O10" value="27"/>
                    <measurement group_id="O11" value="67"/>
                    <measurement group_id="O12" value="58"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="9"/>
                    <measurement group_id="O16" value="10"/>
                    <measurement group_id="O17" value="5"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 4 Neutropenia (ANC &lt;500/mm3)</title>
        <description>Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)</description>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 4 Neutropenia (ANC &lt;500/mm3)</title>
          <description>Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection</title>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="72"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="30"/>
                    <measurement group_id="O12" value="28"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="4"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection</title>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade &gt;=2 Infusion Related Reactions</title>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade &gt;=2 Infusion Related Reactions</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade &gt;=2 Hypersensitivity Reactions</title>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade &gt;=2 Hypersensitivity Reactions</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Gastrointestinal Perforation</title>
        <time_frame>Up to day 60</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O17">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O18">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O19">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastrointestinal Perforation</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="170"/>
                <count group_id="O5" value="242"/>
                <count group_id="O6" value="338"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="140"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="92"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="15"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="6"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Leukocyte Values Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Leukocyte Values Across Study Days (Phase 2)</title>
          <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>10^9 cells/liter(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" spread="3.73"/>
                    <measurement group_id="O2" value="9.41" spread="4.68"/>
                    <measurement group_id="O3" value="10.28" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" spread="5.54"/>
                    <measurement group_id="O2" value="9.00" spread="6.61"/>
                    <measurement group_id="O3" value="9.47" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.44" spread="5.94"/>
                    <measurement group_id="O2" value="13.10" spread="7.17"/>
                    <measurement group_id="O3" value="12.10" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.06" spread="6.73"/>
                    <measurement group_id="O2" value="11.20" spread="5.81"/>
                    <measurement group_id="O3" value="12.48" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Leukocyte Values Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Leukocyte Values Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size.</population>
          <units>10^9 cells/liter(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="228"/>
                    <count group_id="O3" value="332"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="136"/>
                    <count group_id="O6" value="131"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="90"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.18" spread="4.57"/>
                    <measurement group_id="O2" value="10.51" spread="4.83"/>
                    <measurement group_id="O3" value="10.52" spread="4.442"/>
                    <measurement group_id="O4" value="7.83" spread="2.97"/>
                    <measurement group_id="O5" value="8.16" spread="3.42"/>
                    <measurement group_id="O6" value="8.38" spread="4.06"/>
                    <measurement group_id="O7" value="12.01" spread="5.57"/>
                    <measurement group_id="O8" value="12.98" spread="5.72"/>
                    <measurement group_id="O9" value="12.35" spread="5.78"/>
                    <measurement group_id="O10" value="14.26" spread="9.99"/>
                    <measurement group_id="O11" value="9.13" spread="5.112"/>
                    <measurement group_id="O12" value="7.20" spread="5.28"/>
                    <measurement group_id="O13" value="11.52" spread="3.55"/>
                    <measurement group_id="O14" value="12.13" spread="5.27"/>
                    <measurement group_id="O15" value="8.80" spread="2.14"/>
                    <measurement group_id="O16" value="4.80" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="333"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="128"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="92"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.11" spread="5.49"/>
                    <measurement group_id="O2" value="9.47" spread="5.77"/>
                    <measurement group_id="O3" value="9.19" spread="5.82"/>
                    <measurement group_id="O4" value="7.93" spread="2.87"/>
                    <measurement group_id="O5" value="6.76" spread="3.92"/>
                    <measurement group_id="O6" value="6.89" spread="5.10"/>
                    <measurement group_id="O7" value="13.53" spread="7.44"/>
                    <measurement group_id="O8" value="11.62" spread="7.05"/>
                    <measurement group_id="O9" value="11.25" spread="8.42"/>
                    <measurement group_id="O10" value="13.48" spread="10.88"/>
                    <measurement group_id="O11" value="6.44" spread="2.68"/>
                    <measurement group_id="O12" value="6.50" spread="6.36"/>
                    <measurement group_id="O13" value="12.15" spread="4.87"/>
                    <measurement group_id="O14" value="8.30" spread="3.87"/>
                    <measurement group_id="O15" value="9.96" spread="2.92"/>
                    <measurement group_id="O16" value="4.70" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="192"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="63"/>
                    <count group_id="O9" value="66"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="14"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.03" spread="4.68"/>
                    <measurement group_id="O2" value="11.26" spread="6.79"/>
                    <measurement group_id="O3" value="10.47" spread="6.28"/>
                    <measurement group_id="O4" value="10.58" spread="5.86"/>
                    <measurement group_id="O5" value="9.68" spread="4.88"/>
                    <measurement group_id="O6" value="11.18" spread="10.52"/>
                    <measurement group_id="O7" value="13.97" spread="5.57"/>
                    <measurement group_id="O8" value="12.73" spread="7.25"/>
                    <measurement group_id="O9" value="11.90" spread="8.88"/>
                    <measurement group_id="O10" value="22.45" spread="17.05"/>
                    <measurement group_id="O11" value="8.12" spread="2.75"/>
                    <measurement group_id="O12" value="12.84" spread="7.21"/>
                    <measurement group_id="O13" value="11.70" spread="4.81"/>
                    <measurement group_id="O14" value="10.68" spread="10.76"/>
                    <measurement group_id="O15" value="14.45" spread="8.12"/>
                    <measurement group_id="O16" value="16.40" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="39"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.90" spread="6.00"/>
                    <measurement group_id="O2" value="12.17" spread="7.45"/>
                    <measurement group_id="O3" value="31.35" spread="194.41"/>
                    <measurement group_id="O4" value="7.81" spread="2.66"/>
                    <measurement group_id="O5" value="11.56" spread="6.67"/>
                    <measurement group_id="O6" value="11.72" spread="6.28"/>
                    <measurement group_id="O7" value="10.22" spread="3.62"/>
                    <measurement group_id="O8" value="11.15" spread="6.84"/>
                    <measurement group_id="O9" value="10.50" spread="6.44"/>
                    <measurement group_id="O10" value="18.30" spread="0"/>
                    <measurement group_id="O11" value="9.52" spread="5.47"/>
                    <measurement group_id="O12" value="14.10" spread="11.02"/>
                    <measurement group_id="O13" value="11.22" spread="8.67"/>
                    <measurement group_id="O14" value="7.43" spread="2.57"/>
                    <measurement group_id="O15" value="28.44" spread="22.96"/>
                    <measurement group_id="O16" value="7.50" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Hemoglobin Values Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Hemoglobin Values Across Study Days (Phase 2)</title>
          <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>grams/Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.53" spread="20.65"/>
                    <measurement group_id="O2" value="122.19" spread="19.75"/>
                    <measurement group_id="O3" value="122.75" spread="20.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.30" spread="28.23"/>
                    <measurement group_id="O2" value="122.79" spread="20.44"/>
                    <measurement group_id="O3" value="122.61" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.04" spread="22.39"/>
                    <measurement group_id="O2" value="104.11" spread="21.88"/>
                    <measurement group_id="O3" value="105.85" spread="22.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.48" spread="15.30"/>
                    <measurement group_id="O2" value="96.00" spread="21.36"/>
                    <measurement group_id="O3" value="98.20" spread="19.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Hemoglobin Values Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Hemoglobin Values Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
          <units>grams/Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="228"/>
                    <count group_id="O3" value="333"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="136"/>
                    <count group_id="O6" value="131"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="90"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.70" spread="19.85"/>
                    <measurement group_id="O2" value="121.25" spread="20.39"/>
                    <measurement group_id="O3" value="121.06" spread="19.97"/>
                    <measurement group_id="O4" value="127.64" spread="15.27"/>
                    <measurement group_id="O5" value="124.18" spread="20.59"/>
                    <measurement group_id="O6" value="124.76" spread="20.64"/>
                    <measurement group_id="O7" value="114.59" spread="19.03"/>
                    <measurement group_id="O8" value="110.40" spread="22.34"/>
                    <measurement group_id="O9" value="104.19" spread="19.40"/>
                    <measurement group_id="O10" value="121.88" spread="24.00"/>
                    <measurement group_id="O11" value="120.55" spread="18.93"/>
                    <measurement group_id="O12" value="99.00" spread="22.83"/>
                    <measurement group_id="O13" value="111.20" spread="19.01"/>
                    <measurement group_id="O14" value="115.75" spread="21.51"/>
                    <measurement group_id="O15" value="122.00" spread="17.16"/>
                    <measurement group_id="O16" value="111.50" spread="33.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="333"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="128"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="92"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.90" spread="20.72"/>
                    <measurement group_id="O2" value="121.03" spread="20.83"/>
                    <measurement group_id="O3" value="120.57" spread="21.82"/>
                    <measurement group_id="O4" value="123.58" spread="16.89"/>
                    <measurement group_id="O5" value="125.70" spread="20.59"/>
                    <measurement group_id="O6" value="125.61" spread="20.74"/>
                    <measurement group_id="O7" value="101.36" spread="16.90"/>
                    <measurement group_id="O8" value="106.55" spread="21.22"/>
                    <measurement group_id="O9" value="102.46" spread="20.43"/>
                    <measurement group_id="O10" value="114.13" spread="15.57"/>
                    <measurement group_id="O11" value="118.25" spread="21.64"/>
                    <measurement group_id="O12" value="97.13" spread="22.68"/>
                    <measurement group_id="O13" value="103.73" spread="19.49"/>
                    <measurement group_id="O14" value="114.56" spread="17.00"/>
                    <measurement group_id="O15" value="115.33" spread="16.15"/>
                    <measurement group_id="O16" value="113.50" spread="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="192"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="63"/>
                    <count group_id="O9" value="66"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="14"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.66" spread="20.00"/>
                    <measurement group_id="O2" value="104.70" spread="22.93"/>
                    <measurement group_id="O3" value="107.87" spread="23.48"/>
                    <measurement group_id="O4" value="112.15" spread="21.36"/>
                    <measurement group_id="O5" value="106.27" spread="20.25"/>
                    <measurement group_id="O6" value="113.43" spread="27.11"/>
                    <measurement group_id="O7" value="91.16" spread="15.85"/>
                    <measurement group_id="O8" value="95.21" spread="18.30"/>
                    <measurement group_id="O9" value="90.88" spread="18.37"/>
                    <measurement group_id="O10" value="106.75" spread="28.94"/>
                    <measurement group_id="O11" value="111.00" spread="21.87"/>
                    <measurement group_id="O12" value="91.86" spread="19.15"/>
                    <measurement group_id="O13" value="92.85" spread="16.80"/>
                    <measurement group_id="O14" value="109.43" spread="15.54"/>
                    <measurement group_id="O15" value="103.40" spread="20.88"/>
                    <measurement group_id="O16" value="101.50" spread="14.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="39"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.31" spread="15.05"/>
                    <measurement group_id="O2" value="91.50" spread="18.08"/>
                    <measurement group_id="O3" value="96.28" spread="19.50"/>
                    <measurement group_id="O4" value="86.67" spread="17.67"/>
                    <measurement group_id="O5" value="99.58" spread="22.48"/>
                    <measurement group_id="O6" value="88.92" spread="22.72"/>
                    <measurement group_id="O7" value="85.23" spread="10.88"/>
                    <measurement group_id="O8" value="88.74" spread="13.27"/>
                    <measurement group_id="O9" value="88.44" spread="15.13"/>
                    <measurement group_id="O10" value="135.00" spread="0"/>
                    <measurement group_id="O11" value="96.00" spread="11.27"/>
                    <measurement group_id="O12" value="85.20" spread="13.68"/>
                    <measurement group_id="O13" value="99.40" spread="23.03"/>
                    <measurement group_id="O14" value="106.29" spread="12.59"/>
                    <measurement group_id="O15" value="98.50" spread="38.89"/>
                    <measurement group_id="O16" value="82.50" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Platelet Count Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Platelet Count Across Study Days (Phase 2)</title>
          <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>10^9 platelets/liter(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.03" spread="102.22"/>
                    <measurement group_id="O2" value="249.40" spread="100.55"/>
                    <measurement group_id="O3" value="261.50" spread="94.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.86" spread="129.80"/>
                    <measurement group_id="O2" value="304.94" spread="117.17"/>
                    <measurement group_id="O3" value="319.89" spread="116.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.89" spread="155.08"/>
                    <measurement group_id="O2" value="264.03" spread="116.22"/>
                    <measurement group_id="O3" value="257.88" spread="118.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.12" spread="148.66"/>
                    <measurement group_id="O2" value="306.87" spread="119.10"/>
                    <measurement group_id="O3" value="312.14" spread="147.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Platelet Count Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Platelet Count Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
          <units>10^9 platelets/liter(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="227"/>
                    <count group_id="O3" value="332"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="136"/>
                    <count group_id="O6" value="130"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="90"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.56" spread="120.77"/>
                    <measurement group_id="O2" value="278.60" spread="112.15"/>
                    <measurement group_id="O3" value="278.40" spread="120.16"/>
                    <measurement group_id="O4" value="251.03" spread="109.74"/>
                    <measurement group_id="O5" value="271.70" spread="109.63"/>
                    <measurement group_id="O6" value="259.06" spread="115.47"/>
                    <measurement group_id="O7" value="244.11" spread="103.10"/>
                    <measurement group_id="O8" value="251.85" spread="105.45"/>
                    <measurement group_id="O9" value="258.37" spread="100.32"/>
                    <measurement group_id="O10" value="233.00" spread="74.04"/>
                    <measurement group_id="O11" value="221.64" spread="84.86"/>
                    <measurement group_id="O12" value="190.33" spread="77.23"/>
                    <measurement group_id="O13" value="228.40" spread="121.12"/>
                    <measurement group_id="O14" value="278.31" spread="130.65"/>
                    <measurement group_id="O15" value="298.50" spread="114.86"/>
                    <measurement group_id="O16" value="197.00" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="333"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="128"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="92"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.20" spread="137.22"/>
                    <measurement group_id="O2" value="318.16" spread="129.76"/>
                    <measurement group_id="O3" value="311.42" spread="136.44"/>
                    <measurement group_id="O4" value="324.57" spread="154.49"/>
                    <measurement group_id="O5" value="348.96" spread="135.13"/>
                    <measurement group_id="O6" value="330.84" spread="154.22"/>
                    <measurement group_id="O7" value="276.70" spread="111.39"/>
                    <measurement group_id="O8" value="275.84" spread="116.70"/>
                    <measurement group_id="O9" value="268.18" spread="116.49"/>
                    <measurement group_id="O10" value="244.88" spread="73.27"/>
                    <measurement group_id="O11" value="261.00" spread="109.90"/>
                    <measurement group_id="O12" value="225.47" spread="75.84"/>
                    <measurement group_id="O13" value="267.80" spread="132.29"/>
                    <measurement group_id="O14" value="318.25" spread="134.09"/>
                    <measurement group_id="O15" value="421.17" spread="135.03"/>
                    <measurement group_id="O16" value="294.00" spread="127.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="192"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="63"/>
                    <count group_id="O9" value="66"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="14"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.38" spread="143.62"/>
                    <measurement group_id="O2" value="230.44" spread="100.71"/>
                    <measurement group_id="O3" value="222.62" spread="100.21"/>
                    <measurement group_id="O4" value="271.71" spread="124.32"/>
                    <measurement group_id="O5" value="242.40" spread="82.25"/>
                    <measurement group_id="O6" value="223.14" spread="102.57"/>
                    <measurement group_id="O7" value="312.81" spread="155.88"/>
                    <measurement group_id="O8" value="232.97" spread="115.44"/>
                    <measurement group_id="O9" value="226.89" spread="110.91"/>
                    <measurement group_id="O10" value="219.25" spread="77.89"/>
                    <measurement group_id="O11" value="203.63" spread="47.37"/>
                    <measurement group_id="O12" value="133.14" spread="59.74"/>
                    <measurement group_id="O13" value="275.69" spread="150.11"/>
                    <measurement group_id="O14" value="209.00" spread="92.41"/>
                    <measurement group_id="O15" value="306.60" spread="108.91"/>
                    <measurement group_id="O16" value="259.00" spread="39.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="39"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.02" spread="143.38"/>
                    <measurement group_id="O2" value="270.88" spread="102.72"/>
                    <measurement group_id="O3" value="248.60" spread="139.26"/>
                    <measurement group_id="O4" value="264.67" spread="147.97"/>
                    <measurement group_id="O5" value="238.67" spread="125.15"/>
                    <measurement group_id="O6" value="182.58" spread="107.29"/>
                    <measurement group_id="O7" value="332.73" spread="156.61"/>
                    <measurement group_id="O8" value="310.52" spread="155.05"/>
                    <measurement group_id="O9" value="279.31" spread="124.43"/>
                    <measurement group_id="O10" value="267.00" spread="0"/>
                    <measurement group_id="O11" value="281.00" spread="130.09"/>
                    <measurement group_id="O12" value="181.25" spread="53.01"/>
                    <measurement group_id="O13" value="265.00" spread="70.67"/>
                    <measurement group_id="O14" value="235.71" spread="100.19"/>
                    <measurement group_id="O15" value="272.00" spread="26.87"/>
                    <measurement group_id="O16" value="373.00" spread="367.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Total Bilirubin Values Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Total Bilirubin Values Across Study Days (Phase 2)</title>
          <population>Phase 2 Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>micromole/liter (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.07" spread="14.20"/>
                    <measurement group_id="O2" value="11.96" spread="13.59"/>
                    <measurement group_id="O3" value="12.24" spread="15.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.44" spread="10.90"/>
                    <measurement group_id="O2" value="11.87" spread="17.12"/>
                    <measurement group_id="O3" value="9.89" spread="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" spread="17.63"/>
                    <measurement group_id="O2" value="12.43" spread="8.69"/>
                    <measurement group_id="O3" value="14.16" spread="21.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="19.84"/>
                    <measurement group_id="O2" value="7.87" spread="3.44"/>
                    <measurement group_id="O3" value="11.40" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Total Bilirubin Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Total Bilirubin Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="305"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="122"/>
                    <count group_id="O6" value="117"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="82"/>
                    <count group_id="O9" value="84"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.79" spread="7.66"/>
                    <measurement group_id="O2" value="12.02" spread="7.82"/>
                    <measurement group_id="O3" value="12.99" spread="14.20"/>
                    <measurement group_id="O4" value="9.09" spread="4.17"/>
                    <measurement group_id="O5" value="9.93" spread="5.27"/>
                    <measurement group_id="O6" value="10.12" spread="5.95"/>
                    <measurement group_id="O7" value="10.94" spread="8.57"/>
                    <measurement group_id="O8" value="16.89" spread="21.77"/>
                    <measurement group_id="O9" value="16.56" spread="13.46"/>
                    <measurement group_id="O10" value="6.27" spread="2.57"/>
                    <measurement group_id="O11" value="10.10" spread="9.90"/>
                    <measurement group_id="O12" value="7.30" spread="4.77"/>
                    <measurement group_id="O13" value="10.79" spread="7.47"/>
                    <measurement group_id="O14" value="9.92" spread="5.93"/>
                    <measurement group_id="O15" value="9.98" spread="1.68"/>
                    <measurement group_id="O16" value="9.41" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="318"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="116"/>
                    <count group_id="O6" value="121"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="91"/>
                    <count group_id="O9" value="88"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.11" spread="13.11"/>
                    <measurement group_id="O2" value="10.10" spread="6.39"/>
                    <measurement group_id="O3" value="10.21" spread="8.61"/>
                    <measurement group_id="O4" value="9.53" spread="4.67"/>
                    <measurement group_id="O5" value="8.45" spread="5.43"/>
                    <measurement group_id="O6" value="8.38" spread="4.16"/>
                    <measurement group_id="O7" value="14.57" spread="14.93"/>
                    <measurement group_id="O8" value="10.94" spread="10.45"/>
                    <measurement group_id="O9" value="13.98" spread="11.00"/>
                    <measurement group_id="O10" value="7.98" spread="6.18"/>
                    <measurement group_id="O11" value="10.26" spread="8.12"/>
                    <measurement group_id="O12" value="6.96" spread="3.11"/>
                    <measurement group_id="O13" value="12.43" spread="5.19"/>
                    <measurement group_id="O14" value="7.70" spread="5.15"/>
                    <measurement group_id="O15" value="11.40" spread="4.55"/>
                    <measurement group_id="O16" value="9.41" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="177"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="60"/>
                    <count group_id="O9" value="64"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="3"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.47" spread="37.13"/>
                    <measurement group_id="O2" value="11.66" spread="8.09"/>
                    <measurement group_id="O3" value="15.60" spread="48.78"/>
                    <measurement group_id="O4" value="8.66" spread="2.54"/>
                    <measurement group_id="O5" value="11.07" spread="7.15"/>
                    <measurement group_id="O6" value="19.37" spread="47.14"/>
                    <measurement group_id="O7" value="13.20" spread="11.02"/>
                    <measurement group_id="O8" value="10.69" spread="7.93"/>
                    <measurement group_id="O9" value="14.26" spread="18.85"/>
                    <measurement group_id="O10" value="19.24" spread="10.76"/>
                    <measurement group_id="O11" value="16.37" spread="24.60"/>
                    <measurement group_id="O12" value="8.55" spread="2.61"/>
                    <measurement group_id="O13" value="23.09" spread="45.49"/>
                    <measurement group_id="O14" value="10.97" spread="3.53"/>
                    <measurement group_id="O15" value="10.26" spread="4.52"/>
                    <measurement group_id="O16" value="11.97" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="37"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="2"/>
                    <count group_id="O14" value="6"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.66" spread="11.00"/>
                    <measurement group_id="O2" value="11.74" spread="13.86"/>
                    <measurement group_id="O3" value="19.24" spread="38.66"/>
                    <measurement group_id="O4" value="9.69" spread="0.99"/>
                    <measurement group_id="O5" value="25.48" spread="38.28"/>
                    <measurement group_id="O6" value="31.19" spread="71.38"/>
                    <measurement group_id="O7" value="9.69" spread="9.13"/>
                    <measurement group_id="O8" value="9.44" spread="9.44"/>
                    <measurement group_id="O9" value="10.54" spread="8.19"/>
                    <measurement group_id="O10" value="13.68" spread="0"/>
                    <measurement group_id="O11" value="3.42" spread="0"/>
                    <measurement group_id="O12" value="8.89" spread="3.71"/>
                    <measurement group_id="O13" value="4.27" spread="1.21"/>
                    <measurement group_id="O14" value="6.56" spread="2.52"/>
                    <measurement group_id="O15" value="13.68" spread="14.51"/>
                    <measurement group_id="O16" value="7.70" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)</title>
          <population>Phase 2 Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>International Units/Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.58" spread="32.40"/>
                    <measurement group_id="O2" value="57.88" spread="33.35"/>
                    <measurement group_id="O3" value="60.39" spread="36.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.52" spread="61.41"/>
                    <measurement group_id="O2" value="90.01" spread="127.42"/>
                    <measurement group_id="O3" value="78.34" spread="63.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.12" spread="25.17"/>
                    <measurement group_id="O2" value="188.65" spread="941.96"/>
                    <measurement group_id="O3" value="88.96" spread="329.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.00" spread="82.78"/>
                    <measurement group_id="O2" value="40.69" spread="35.70"/>
                    <measurement group_id="O3" value="100.05" spread="337.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD)[vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="312"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="125"/>
                    <count group_id="O6" value="121"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="84"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.54" spread="33.67"/>
                    <measurement group_id="O2" value="54.73" spread="35.99"/>
                    <measurement group_id="O3" value="60.61" spread="39.15"/>
                    <measurement group_id="O4" value="51.54" spread="28.35"/>
                    <measurement group_id="O5" value="58.58" spread="45.19"/>
                    <measurement group_id="O6" value="47.80" spread="29.38"/>
                    <measurement group_id="O7" value="61.13" spread="38.23"/>
                    <measurement group_id="O8" value="77.66" spread="163.34"/>
                    <measurement group_id="O9" value="57.68" spread="36.02"/>
                    <measurement group_id="O10" value="47.00" spread="37.44"/>
                    <measurement group_id="O11" value="47.36" spread="24.52"/>
                    <measurement group_id="O12" value="35.47" spread="22.96"/>
                    <measurement group_id="O13" value="58.77" spread="42.03"/>
                    <measurement group_id="O14" value="58.33" spread="27.48"/>
                    <measurement group_id="O15" value="114.00" spread="134.17"/>
                    <measurement group_id="O16" value="36.50" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="320"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="116"/>
                    <count group_id="O6" value="122"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="91"/>
                    <count group_id="O9" value="88"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.21" spread="74.93"/>
                    <measurement group_id="O2" value="69.30" spread="65.10"/>
                    <measurement group_id="O3" value="78.29" spread="108.57"/>
                    <measurement group_id="O4" value="52.79" spread="39.90"/>
                    <measurement group_id="O5" value="66.47" spread="63.95"/>
                    <measurement group_id="O6" value="76.77" spread="178.97"/>
                    <measurement group_id="O7" value="65.39" spread="52.27"/>
                    <measurement group_id="O8" value="94.76" spread="136.93"/>
                    <measurement group_id="O9" value="124.83" spread="270.78"/>
                    <measurement group_id="O10" value="58.00" spread="69.65"/>
                    <measurement group_id="O11" value="51.33" spread="33.72"/>
                    <measurement group_id="O12" value="52.93" spread="48.68"/>
                    <measurement group_id="O13" value="76.73" spread="35.24"/>
                    <measurement group_id="O14" value="75.88" spread="51.15"/>
                    <measurement group_id="O15" value="74.50" spread="65.31"/>
                    <measurement group_id="O16" value="32.50" spread="19.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="177"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="60"/>
                    <count group_id="O9" value="64"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="3"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.95" spread="131.49"/>
                    <measurement group_id="O2" value="72.27" spread="232.21"/>
                    <measurement group_id="O3" value="75.08" spread="162.60"/>
                    <measurement group_id="O4" value="38.73" spread="20.81"/>
                    <measurement group_id="O5" value="73.42" spread="152.57"/>
                    <measurement group_id="O6" value="126.70" spread="312.36"/>
                    <measurement group_id="O7" value="50.00" spread="37.36"/>
                    <measurement group_id="O8" value="49.89" spread="46.50"/>
                    <measurement group_id="O9" value="98.84" spread="276.99"/>
                    <measurement group_id="O10" value="128.25" spread="180.12"/>
                    <measurement group_id="O11" value="45.29" spread="26.30"/>
                    <measurement group_id="O12" value="52.29" spread="43.10"/>
                    <measurement group_id="O13" value="33.17" spread="9.68"/>
                    <measurement group_id="O14" value="64.08" spread="58.97"/>
                    <measurement group_id="O15" value="40.00" spread="41.87"/>
                    <measurement group_id="O16" value="15.00" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="37"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="2"/>
                    <count group_id="O14" value="6"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.76" spread="102.66"/>
                    <measurement group_id="O2" value="163.83" spread="817.08"/>
                    <measurement group_id="O3" value="363.69" spread="2565.77"/>
                    <measurement group_id="O4" value="80.33" spread="65.90"/>
                    <measurement group_id="O5" value="347.60" spread="982.89"/>
                    <measurement group_id="O6" value="72.17" spread="86.39"/>
                    <measurement group_id="O7" value="35.24" spread="21.51"/>
                    <measurement group_id="O8" value="40.07" spread="25.67"/>
                    <measurement group_id="O9" value="38.19" spread="29.82"/>
                    <measurement group_id="O10" value="25.00" spread="0"/>
                    <measurement group_id="O11" value="20.00" spread="0"/>
                    <measurement group_id="O12" value="31.20" spread="16.69"/>
                    <measurement group_id="O13" value="25.50" spread="13.44"/>
                    <measurement group_id="O14" value="46.67" spread="39.87"/>
                    <measurement group_id="O15" value="69.00" spread="57.98"/>
                    <measurement group_id="O16" value="46.00" spread="42.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)</title>
          <population>Phase 2 Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>International Units/Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.93" spread="34.75"/>
                    <measurement group_id="O2" value="50.25" spread="36.69"/>
                    <measurement group_id="O3" value="48.25" spread="30.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.34" spread="42.15"/>
                    <measurement group_id="O2" value="86.08" spread="148.46"/>
                    <measurement group_id="O3" value="74.20" spread="78.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.00" spread="37.75"/>
                    <measurement group_id="O2" value="106.17" spread="282.61"/>
                    <measurement group_id="O3" value="121.58" spread="507.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.30" spread="112.36"/>
                    <measurement group_id="O2" value="58.63" spread="48.92"/>
                    <measurement group_id="O3" value="64.82" spread="78.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
          <units>International Units/Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="312"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="125"/>
                    <count group_id="O6" value="121"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="85"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="15"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.69" spread="37.36"/>
                    <measurement group_id="O2" value="51.08" spread="35.87"/>
                    <measurement group_id="O3" value="52.15" spread="36.66"/>
                    <measurement group_id="O4" value="46.69" spread="34.09"/>
                    <measurement group_id="O5" value="54.22" spread="42.27"/>
                    <measurement group_id="O6" value="49.43" spread="39.98"/>
                    <measurement group_id="O7" value="45.00" spread="35.07"/>
                    <measurement group_id="O8" value="59.13" spread="96.74"/>
                    <measurement group_id="O9" value="41.75" spread="29.42"/>
                    <measurement group_id="O10" value="33.50" spread="18.45"/>
                    <measurement group_id="O11" value="43.00" spread="31.81"/>
                    <measurement group_id="O12" value="22.27" spread="25.57"/>
                    <measurement group_id="O13" value="46.77" spread="31.49"/>
                    <measurement group_id="O14" value="45.33" spread="40.77"/>
                    <measurement group_id="O15" value="103.33" spread="153.15"/>
                    <measurement group_id="O16" value="33.50" spread="30.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="320"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="116"/>
                    <count group_id="O6" value="122"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="91"/>
                    <count group_id="O9" value="88"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.45" spread="139.06"/>
                    <measurement group_id="O2" value="72.32" spread="60.25"/>
                    <measurement group_id="O3" value="74.62" spread="77.09"/>
                    <measurement group_id="O4" value="59.38" spread="51.04"/>
                    <measurement group_id="O5" value="68.69" spread="51.45"/>
                    <measurement group_id="O6" value="86.13" spread="146.92"/>
                    <measurement group_id="O7" value="52.22" spread="52.86"/>
                    <measurement group_id="O8" value="69.75" spread="102.66"/>
                    <measurement group_id="O9" value="84.68" spread="152.72"/>
                    <measurement group_id="O10" value="40.86" spread="26.62"/>
                    <measurement group_id="O11" value="45.17" spread="23.35"/>
                    <measurement group_id="O12" value="38.50" spread="45.66"/>
                    <measurement group_id="O13" value="62.27" spread="33.29"/>
                    <measurement group_id="O14" value="53.06" spread="44.57"/>
                    <measurement group_id="O15" value="103.67" spread="174.35"/>
                    <measurement group_id="O16" value="32.00" spread="28.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="177"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="60"/>
                    <count group_id="O9" value="64"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="3"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.09" spread="71.11"/>
                    <measurement group_id="O2" value="79.98" spread="131.21"/>
                    <measurement group_id="O3" value="93.82" spread="155.98"/>
                    <measurement group_id="O4" value="52.60" spread="48.06"/>
                    <measurement group_id="O5" value="97.73" spread="205.87"/>
                    <measurement group_id="O6" value="101.00" spread="156.42"/>
                    <measurement group_id="O7" value="62.11" spread="42.15"/>
                    <measurement group_id="O8" value="64.80" spread="68.11"/>
                    <measurement group_id="O9" value="98.31" spread="163.08"/>
                    <measurement group_id="O10" value="257.25" spread="454.57"/>
                    <measurement group_id="O11" value="66.14" spread="51.89"/>
                    <measurement group_id="O12" value="47.57" spread="53.53"/>
                    <measurement group_id="O13" value="45.83" spread="24.52"/>
                    <measurement group_id="O14" value="85.75" spread="104.56"/>
                    <measurement group_id="O15" value="24.33" spread="7.51"/>
                    <measurement group_id="O16" value="14.00" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="37"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="1"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="2"/>
                    <count group_id="O14" value="6"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.71" spread="107.24"/>
                    <measurement group_id="O2" value="86.04" spread="155.72"/>
                    <measurement group_id="O3" value="155.63" spread="759.34"/>
                    <measurement group_id="O4" value="60.00" spread="36.37"/>
                    <measurement group_id="O5" value="127.30" spread="173.38"/>
                    <measurement group_id="O6" value="88.17" spread="127.32"/>
                    <measurement group_id="O7" value="46.24" spread="48.87"/>
                    <measurement group_id="O8" value="46.85" spread="28.14"/>
                    <measurement group_id="O9" value="48.51" spread="39.44"/>
                    <measurement group_id="O10" value="17.00" spread="0"/>
                    <measurement group_id="O11" value="39.00" spread="0"/>
                    <measurement group_id="O12" value="36.00" spread="32.99"/>
                    <measurement group_id="O13" value="25.50" spread="0.71"/>
                    <measurement group_id="O14" value="58.33" spread="33.66"/>
                    <measurement group_id="O15" value="48.00" spread="12.73"/>
                    <measurement group_id="O16" value="83.50" spread="85.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Creatinine Values Across Study Days (Phase 2)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Sarilumab 200mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Sarilumab 400mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Creatinine Values Across Study Days (Phase 2)</title>
          <population>Phase 2 population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>micromole/liter (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.81" spread="142.13"/>
                    <measurement group_id="O2" value="137.20" spread="148.58"/>
                    <measurement group_id="O3" value="158.18" spread="242.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.12" spread="184.77"/>
                    <measurement group_id="O2" value="151.86" spread="163.45"/>
                    <measurement group_id="O3" value="164.62" spread="246.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.56" spread="260.81"/>
                    <measurement group_id="O2" value="168.74" spread="201.28"/>
                    <measurement group_id="O3" value="155.23" spread="163.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.52" spread="138.14"/>
                    <measurement group_id="O2" value="138.02" spread="121.95"/>
                    <measurement group_id="O3" value="118.56" spread="133.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Observed Creatinine Values Across Study Days (Phase 3)</title>
        <time_frame>Days 1, 4, 15 and 29</time_frame>
        <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3 Cohort 1: Placebo - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O2">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O3">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
          </group>
          <group group_id="O4">
            <title>Phase 3 Cohort 1: Placebo - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O5">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O6">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
          </group>
          <group group_id="O7">
            <title>Phase 3 Cohort 1: Placebo - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O8">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O9">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
          </group>
          <group group_id="O10">
            <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O11">
            <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O12">
            <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised</title>
            <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
          </group>
          <group group_id="O13">
            <title>Phase 3 Cohort 2: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O14">
            <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
          </group>
          <group group_id="O15">
            <title>Phase 3 Cohort 3: Placebo</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
          <group group_id="O16">
            <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
            <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Observed Creatinine Values Across Study Days (Phase 3)</title>
          <population>Phase 3 population. Only those participants with data available at the specified time points were analyzed. Phase 3 Cohort 3 data was not summarized due to insufficient sample size</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="95"/>
                <count group_id="O9" value="92"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="15"/>
                <count group_id="O13" value="15"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="237"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="134"/>
                    <count group_id="O6" value="134"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="88"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.64" spread="145.57"/>
                    <measurement group_id="O2" value="141.97" spread="187.40"/>
                    <measurement group_id="O3" value="121.75" spread="132.43"/>
                    <measurement group_id="O4" value="109.14" spread="196.52"/>
                    <measurement group_id="O5" value="174.92" spread="802.76"/>
                    <measurement group_id="O6" value="111.63" spread="168.83"/>
                    <measurement group_id="O7" value="187.93" spread="232.11"/>
                    <measurement group_id="O8" value="308.63" spread="308.42"/>
                    <measurement group_id="O9" value="280.83" spread="280.30"/>
                    <measurement group_id="O10" value="259.01" spread="401.63"/>
                    <measurement group_id="O11" value="265.36" spread="396.16"/>
                    <measurement group_id="O12" value="401.87" spread="294.63"/>
                    <measurement group_id="O13" value="103.19" spread="74.60"/>
                    <measurement group_id="O14" value="78.79" spread="30.71"/>
                    <measurement group_id="O15" value="108.73" spread="92.72"/>
                    <measurement group_id="O16" value="497.25" spread="621.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="335"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="129"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="92"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="12"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="15"/>
                    <count group_id="O14" value="16"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.77" spread="144.10"/>
                    <measurement group_id="O2" value="129.08" spread="145.08"/>
                    <measurement group_id="O3" value="128.56" spread="127.48"/>
                    <measurement group_id="O4" value="93.23" spread="151.97"/>
                    <measurement group_id="O5" value="101.45" spread="129.88"/>
                    <measurement group_id="O6" value="113.30" spread="152.19"/>
                    <measurement group_id="O7" value="176.80" spread="160.17"/>
                    <measurement group_id="O8" value="314.53" spread="352.59"/>
                    <measurement group_id="O9" value="281.92" spread="310.48"/>
                    <measurement group_id="O10" value="267.96" spread="479.59"/>
                    <measurement group_id="O11" value="205.38" spread="249.38"/>
                    <measurement group_id="O12" value="395.09" spread="246.34"/>
                    <measurement group_id="O13" value="121.40" spread="84.33"/>
                    <measurement group_id="O14" value="99.28" spread="96.74"/>
                    <measurement group_id="O15" value="83.24" spread="62.60"/>
                    <measurement group_id="O16" value="458.80" spread="576.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="195"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="32"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="63"/>
                    <count group_id="O9" value="65"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="13"/>
                    <count group_id="O14" value="14"/>
                    <count group_id="O15" value="5"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.06" spread="175.53"/>
                    <measurement group_id="O2" value="136.98" spread="149.03"/>
                    <measurement group_id="O3" value="120.96" spread="134.39"/>
                    <measurement group_id="O4" value="151.11" spread="284.59"/>
                    <measurement group_id="O5" value="175.09" spread="243.54"/>
                    <measurement group_id="O6" value="111.99" spread="97.29"/>
                    <measurement group_id="O7" value="160.94" spread="198.07"/>
                    <measurement group_id="O8" value="179.87" spread="183.06"/>
                    <measurement group_id="O9" value="170.10" spread="198.20"/>
                    <measurement group_id="O10" value="142.32" spread="115.06"/>
                    <measurement group_id="O11" value="137.46" spread="99.29"/>
                    <measurement group_id="O12" value="270.39" spread="176.43"/>
                    <measurement group_id="O13" value="116.96" spread="92.34"/>
                    <measurement group_id="O14" value="86.06" spread="64.78"/>
                    <measurement group_id="O15" value="136.49" spread="110.96"/>
                    <measurement group_id="O16" value="311.61" spread="396.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="39"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="5"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="2"/>
                    <count group_id="O16" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.14" spread="140.37"/>
                    <measurement group_id="O2" value="124.97" spread="124.62"/>
                    <measurement group_id="O3" value="100.02" spread="107.10"/>
                    <measurement group_id="O4" value="122.88" spread="161.56"/>
                    <measurement group_id="O5" value="205.17" spread="269.33"/>
                    <measurement group_id="O6" value="143.62" spread="98.50"/>
                    <measurement group_id="O7" value="128.74" spread="191.15"/>
                    <measurement group_id="O8" value="125.21" spread="128.22"/>
                    <measurement group_id="O9" value="197.65" spread="655.38"/>
                    <measurement group_id="O10" value="80.44" spread="0"/>
                    <measurement group_id="O11" value="116.69" spread="32.20"/>
                    <measurement group_id="O12" value="195.01" spread="108.79"/>
                    <measurement group_id="O13" value="55.69" spread="15.14"/>
                    <measurement group_id="O14" value="78.30" spread="40.12"/>
                    <measurement group_id="O15" value="65.86" spread="11.88"/>
                    <measurement group_id="O16" value="276.25" spread="346.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug to Day 60</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 2: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="E2">
          <title>Phase 2: Sarilumab 200mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="E3">
          <title>Phase 2: Sarilumab 400mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection and one of the following disease strata:&#xD;
Severe disease&#xD;
Critical disease&#xD;
Multi-system organ dysfunction/Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="E4">
          <title>Phase 3 Cohort 1: Placebo - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="E5">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="E6">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Critical</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Critical disease (suppl. O2 by non-rebreather/high-flow cannula or invasive/non-invasive ventilation or treatment in ICU)</description>
        </group>
        <group group_id="E7">
          <title>Phase 3 Cohort 1: Placebo - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="E8">
          <title>Phase 3 Cohort 1: Sarilumab 200mg IV - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="E9">
          <title>Phase 3 Cohort 1: Sarilumab 400mg IV - Severe</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Severe disease (suppl. O2 by nasal cannula, face mask, or similar O2 delivery device)</description>
        </group>
        <group group_id="E10">
          <title>Phase 3 Cohort 1: Placebo - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="E11">
          <title>Phase 3 Cohort 1: Sarilumab 200 mg IV - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="E12">
          <title>Phase 3 Cohort 1: Sarilumab 400 mg IV - MSOD</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Multi-system organ dysfunction (MSOD) [vasopressors, extracorporeal life support, or renal replacement therapy]</description>
        </group>
        <group group_id="E13">
          <title>Phase 3 Cohort 1: Placebo - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="E14">
          <title>Phase 3 Cohort 1: Sarilumab 200 mg IV - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="E15">
          <title>Phase 3 Cohort 1: Sarilumab 400 mg IV - Immunocompromised</title>
          <description>Hospitalized with SARS-CoV-2 infection and in the following disease strata:&#xD;
-Immunocompromised or on immunosuppressive treatment</description>
        </group>
        <group group_id="E16">
          <title>Phase 3 Cohort 2: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
        </group>
        <group group_id="E17">
          <title>Phase 3 Cohort 2: Sarilumab 800 mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring mechanical ventilation due to COVID-19</description>
        </group>
        <group group_id="E18">
          <title>Phase 3 Cohort 3: Placebo</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
        </group>
        <group group_id="E19">
          <title>Phase 3 Cohort 3: Sarilumab 800 mg IV</title>
          <description>Hospitalized with SARS-CoV-2 infection requiring high-Intensity oxygen therapy without Mechanical Ventilation at baseline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="242"/>
                <counts group_id="E6" subjects_affected="114" subjects_at_risk="338"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="137"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="46"/>
                <counts group_id="E11" subjects_affected="40" subjects_at_risk="95"/>
                <counts group_id="E12" subjects_affected="40" subjects_at_risk="92"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="119" subjects_at_risk="242"/>
                <counts group_id="E6" subjects_affected="183" subjects_at_risk="338"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="30" subjects_at_risk="137"/>
                <counts group_id="E10" subjects_affected="27" subjects_at_risk="46"/>
                <counts group_id="E11" subjects_affected="67" subjects_at_risk="95"/>
                <counts group_id="E12" subjects_affected="58" subjects_at_risk="92"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E6" events="26" subjects_affected="25" subjects_at_risk="338"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E11" events="9" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E12" events="9" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Antithrombin III deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine storm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="170"/>
                <counts group_id="E5" events="19" subjects_affected="19" subjects_at_risk="242"/>
                <counts group_id="E6" events="23" subjects_affected="23" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E11" events="12" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E12" events="10" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacterial tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Achromobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="338"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Coronavirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Corynebacterium infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterobacter pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Morganella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia acinetobacter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia proteus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia serratia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Serratia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Spinal cord infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stoma site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Viral cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tracheal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Klebsiella test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterobacter test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterococcus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Brachial plexopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Encephalitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intensive care unit acquired weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Seizure like phenomena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neuropsychiatric symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E6" events="17" subjects_affected="17" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="187"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="170"/>
                <counts group_id="E5" events="24" subjects_affected="23" subjects_at_risk="242"/>
                <counts group_id="E6" events="22" subjects_affected="22" subjects_at_risk="338"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E11" events="10" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E12" events="7" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="338"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E6" events="12" subjects_affected="9" subjects_at_risk="338"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acquired diaphragmatic eventration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cystic lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar damage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory tract oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Livedo reticularis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Distributive shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="242"/>
                <counts group_id="E6" subjects_affected="83" subjects_at_risk="338"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="46"/>
                <counts group_id="E11" subjects_affected="23" subjects_at_risk="95"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="92"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="187"/>
                <counts group_id="E3" events="31" subjects_affected="30" subjects_at_risk="180"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="170"/>
                <counts group_id="E5" events="38" subjects_affected="36" subjects_at_risk="242"/>
                <counts group_id="E6" events="40" subjects_affected="36" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="15" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E11" events="15" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E12" events="13" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="41" subjects_affected="38" subjects_at_risk="187"/>
                <counts group_id="E3" events="32" subjects_affected="30" subjects_at_risk="180"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="170"/>
                <counts group_id="E5" events="46" subjects_affected="42" subjects_at_risk="242"/>
                <counts group_id="E6" events="53" subjects_affected="51" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="8" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E10" events="9" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E12" events="13" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="25" subjects_affected="24" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Adminstrator</name_or_title>
      <organization>Regeneron Pharmaceuticals, Inc.</organization>
      <phone>844-734-6643</phone>
      <email>clinicaltrials@regeneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

